An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty

Trial Profile

An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Precocious puberty
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 26 Feb 2018 Planned End Date changed from 27 Feb 2018 to 30 Sep 2018.
    • 26 Feb 2018 Planned primary completion date changed from 27 Feb 2018 to 30 Sep 2018.
    • 30 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top